NEOLISE Renewal Protocol Faces FDA Approval Questions

NEOLISE, a prescription-dependent compounded peptide protocol, has been gaining attention for its claims of addressing visible skin aging and hair thinning among adults over 30. This review explores the NEOLISE Renewal protocol, its pricing, and the FDA context surrounding its use.

NEOLISE markets its product to individuals experiencing signs of skin aging or hair thinning after the age of 30. The protocol combines four peptides, GHK-Cu, BPC-157, TB-500, and KPV, into a compounded formula for intramuscular injection. NEOLISE operates through a provider-review and pharmacy-dispensing pathway, with plans priced at $239 to $299 per month, depending on the term selected. Plans for a 3-month term cost $897, a 6-month term $1,614, and a 12-month term $2,868.

The NEOLISE Renewal protocol is not FDA-approved, and the peptides used in the formulation do not have such approval either. According to NEOLISE, compounded drugs are not regulated as finished products by the FDA. This raises concerns about the safety, quality, and regulatory compliance of the product.

NEOLISE is operated by Omni Health Ventures Inc., a Wyoming S-Corporation. The company's Terms of Use state that it is not a medical practice, healthcare provider, pharmacy, or licensed medical entity. Instead, NEOLISE connects customers with a third-party telehealth platform, a licensed medical group, and a licensed compounding pharmacy. However, the specific legal names and license numbers of these entities are not publicly available, adding to the uncertainty around the product's delivery.

The NEOLISE Renewal protocol includes the following peptides: - GHK-Cu (copper tripeptide): NEOLISE attributes collagen-, hair-, and gene-expression-related mechanisms to GHK-Cu. However, the available evidence includes ingredient-level laboratory and topical-application research, which does not establish the outcomes of a specific 10mg dose delivered subcutaneously as part of a four-peptide compounded mixture. - BPC-157 (Body Protection Compound): In briefing materials for the July 23-24, 2026, Pharmacy Compounding Advisory Committee, FDA staff proposed that BPC-157 not be added to the Section 503A Bulks List, citing chemical-characterization gaps, insufficient effectiveness evidence, and safety concerns. The committee's subsequent recommendation was advisory and nonbinding. - TB-500 (Thymosin Beta-4): NEOLISE describes TB-500 as supporting cell migration and helping repair cells. Similarly, the committee's recommendation for TB-500 was advisory and nonbinding. - KPV (the three-amino-acid tail of alpha-MSH): NEOLISE attributes specific tissue-renewal-speed claims to KPV, but the available evidence does not establish the outcomes of the specific formulation used.

In summary, NEOLISE Renewal is a compounded peptide protocol marketed to adults over 30 experiencing visible skin aging or hair thinning. While the product offers a unique approach, the lack of FDA approval and the unavailability of specific identities of the medical group and pharmacy add layers of uncertainty. Prospective users should carefully consider the risks and benefits before committing to the program.